Gilead Sciences, Inc.-Product Pipeline Review-2016

Gilead Sciences, Inc.-Product Pipeline Review-2016


  • Products Id :- GMDHC07983CDB
  • |
  • Pages: 138
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Gilead Sciences, Inc.-Product Pipeline Review-2016', provides an overview of the Gilead Sciences, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Gilead Sciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Gilead Sciences, Inc.

The report provides overview of Gilead Sciences, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Gilead Sciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Gilead Sciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gilead Sciences, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gilead Sciences, Inc.'s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Gilead Sciences, Inc. Snapshot 6

Gilead Sciences, Inc. Overview 6

Key Information 6

Key Facts 6

Gilead Sciences, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Gilead Sciences, Inc.-Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products-Monotherapy 13

Pipeline Products-Combination Treatment Modalities 14

Pipeline Products-Partnered Products 15

Pipeline Products-Out-Licensed Products 17

Gilead Sciences, Inc.-Pipeline Products Glance 19

Gilead Sciences, Inc.-Late Stage Pipeline Products 19

Gilead Sciences, Inc.-Clinical Stage Pipeline Products 21

Gilead Sciences, Inc.-Early Stage Pipeline Products 23

Gilead Sciences, Inc.-Drug Profiles 25

(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide) 25

(emtricitabine + tenofovir alafenamide fumarate) 26

(sofosbuvir + velpatasvir) 27

tenofovir alafenamide 30

(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) 32

(emtricitabine + GS-9883 + tenofovir alafenamide) 34

(GS-9857 + sofosbuvir + velpatasvir) 35

ambrisentan 37

eleclazine 39

GS-5745 41

idelalisib 43

momelotinib dihydrochloride 46

acalisib 49

entospletinib 50

GS-4774 51

presatovir 52

ranolazine ER 53

regadenoson 56

selonsertib 58

selonsertib + simtuzumab 59

simtuzumab 60

vesatolimod 62

GS-5829 64

GS-5734 65

GS-9674 66

GS-9876 68

ONO-4059 69

GS-459679 71

GS-548202 72

GS-5759 73

GS-607601 74

GS-8374 75

GS-967 76

GS-986 77

Monoclonal Antibodies 1 for Oncology 78

Monoclonal Antibody for HIV / AIDS 79

Monoclonal Antibody to Target HIV-Envelope and CD3 for HIV 80

Px-103 81

Small Molecule to Inhibit Histone Deacetylation for Oncology 82

Small Molecule to Inhibit Histone Methyltransferase for Oncology 83

GS-563253 84

GS-599220 85

Small Molecule for RSV 86

Small Molecule to Inhibit NS4B Protein for HCV 87

Small Molecules for Hepatitis C Infection 88

Small Molecules to Inhibit NS3 Protease for Hepatitis C 89

Small Molecules to Inhibit NS5B for Hepatitis C 90

Gilead Sciences, Inc.-Pipeline Analysis 91

Gilead Sciences, Inc.-Pipeline Products by Target 91

Gilead Sciences, Inc.-Pipeline Products by Route of Administration 94

Gilead Sciences, Inc.-Pipeline Products by Molecule Type 95

Gilead Sciences, Inc.-Pipeline Products by Mechanism of Action 96

Gilead Sciences, Inc.-Recent Pipeline Updates 98

Gilead Sciences, Inc.-Dormant Projects 123

Gilead Sciences, Inc.-Discontinued Pipeline Products 125

Discontinued Pipeline Product Profiles 125

Gilead Sciences, Inc.-Locations And Subsidiaries 129

Head Office 129

Other Locations & Subsidiaries 129

Appendix 134

Methodology 134

Coverage 134

Secondary Research 134

Primary Research 134

Expert Panel Validation 134

Contact Us 134

Disclaimer 135

List of Figures

Gilead Sciences, Inc.-Pipeline by Top 10 Indication, 2016 11

Gilead Sciences, Inc.-Pipeline by Stage of Development, 2016 15

Gilead Sciences, Inc.-Monotherapy Products in Pipeline, 2016 16

Gilead Sciences, Inc.-Combination Treatment Modalities in Pipeline, 2016 17

Gilead Sciences, Inc.-Partnered Products in Pipeline, 2016 18

Gilead Sciences, Inc.-Out-Licensed Products in Pipeline, 2016 20

Gilead Sciences, Inc.-Pipeline by Top 10 Target, 2016 94

Gilead Sciences, Inc.-Pipeline by Route of Administration, 2016 97

Gilead Sciences, Inc.-Pipeline by Molecule Type, 2016 98

Gilead Sciences, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2016 99

List of Tables

Gilead Sciences, Inc., Key Information 9

Gilead Sciences, Inc., Key Facts 9

Gilead Sciences, Inc.-Pipeline by Indication, 2016 11

Gilead Sciences, Inc.-Pipeline by Stage of Development, 2016 15

Gilead Sciences, Inc.-Monotherapy Products in Pipeline, 2016 16

Gilead Sciences, Inc.-Combination Treatment Modalities in Pipeline, 2016 17

Gilead Sciences, Inc.-Partnered Products in Pipeline, 2016 18

Gilead Sciences, Inc.-Partnered Products/ Combination Treatment Modalities, 2016 19

Gilead Sciences, Inc.-Out-Licensed Products in Pipeline, 2016 20

Gilead Sciences, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2016 21

Gilead Sciences, Inc.-Pre-Registration, 2016 22

Gilead Sciences, Inc.-Phase III, 2016 23

Gilead Sciences, Inc.-Phase II, 2016 24

Gilead Sciences, Inc.-Phase I, 2016 25

Gilead Sciences, Inc.-Preclinical, 2016 26

Gilead Sciences, Inc.-Discovery, 2016 27

Gilead Sciences, Inc.-Pipeline by Target, 2016 94

Gilead Sciences, Inc.-Pipeline by Route of Administration, 2016 97

Gilead Sciences, Inc.-Pipeline by Molecule Type, 2016 98

Gilead Sciences, Inc.-Pipeline Products by Mechanism of Action, 2016 99

Gilead Sciences, Inc.-Recent Pipeline Updates, 2016 101

Gilead Sciences, Inc.-Dormant Developmental Projects,2016 126

Gilead Sciences, Inc.-Discontinued Pipeline Products, 2016 128

Gilead Sciences, Inc., Other Locations 132

Gilead Sciences, Inc., Subsidiaries 133

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Gilead Sciences, Inc.; Gilead Sciences, Inc. - Key Therapeutics; Gilead Sciences, Inc. - Pipeline Overview and Promising Molecules; Gilead Sciences, Inc. - News; Gilead Sciences, Inc. - Latest Updates; Gilead Sciences, Inc. - Pipeline; Gilead Sciences, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 96120
Site License
USD 3000 INR 192240
Corporate User License
USD 4500 INR 288360

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com